Informations générales (source: ClinicalTrials.gov)
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study (ALTREM)
Interventional
Phase 1
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
septembre 2019
janvier 2026
07 août 2024
Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy
constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within
a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%.
Median PFS grade III meningioma is approximate 3 years.
Alpelisib is a well-tolerated Phosphoinositide 3-kinase α (Pi3Kα) specific inhibitor.
However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin
(mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative
effect without any radiologic response in most treated patients.
Trametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for
recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily.
In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via
caspase activity.
These results strongly suggest the relevance to combine Alpelisib and Trametinib in
aggressive and recurrent meningiomas.
Alpelisib and Trametinib combination has not been studied to date, despite each drugs
have been separately studied in phase 3.
Multicenter, open label, dose-finding phase I study of Alpelisib in combination with
Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered
daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or
decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine
maximal tolerated dose (MTD) and recommended dose.
Primary Objective is to determine the safety profile and tolerability of Alpelisib and
Trametinib given in combination in patients with aggressive and refractory meningiomas in
terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille - 13354 - Marseille - France | Thomas GRAILLON, PH | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Histologically proven meningioma grade I, II and III
- Progression is defined as growing meningiomas on 2 different Magnetic Resonance
Imaging (MRI) 3 to 6 months apart
- Patients must have failed surgery, and not amenable to a new curative intended
surgery
- Patients must have failed radiotherapy and/or radiosurgery
- Patients who have given their written consent
- No contra indication to Alpelisib and Trametinib
- No receiving other investigational agents
- Written informed consent
- Adequate bone marrow function
- Adequate liver function as shown by
- Adequate renal function
- Histologically proven meningioma grade I, II and III
- Progression is defined as growing meningiomas on 2 different Magnetic Resonance
Imaging (MRI) 3 to 6 months apart
- Patients must have failed surgery, and not amenable to a new curative intended
surgery
- Patients must have failed radiotherapy and/or radiosurgery
- Patients who have given their written consent
- No contra indication to Alpelisib and Trametinib
- No receiving other investigational agents
- Written informed consent
- Adequate bone marrow function
- Adequate liver function as shown by
- Adequate renal function
- Contra indication to Alpelisib and Trametinib
- Women of child-bearing age who are using no effective means of contraception
- Pregnant or breast-feeding women
- Patients receiving other investigational agents
- Known intolerance or hypersensitivity to Alpelisib and Trametinib
- Uncontrolled diabetes mellitus
- Patients who have any severe and uncontrolled medical condition
- Patients receiving chronic treatment with immunosuppressives
- Patients with a known history of HIV seropositivity
- Patients who have a history of another primary malignancy less than or equal to 3
years, with
- the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix